文献速递颈动脉与弓上血管

单中心TCAR围手术期与随访结局

Perioperative and Follow-Up TCAR Outcomes of a Single Institution.
PubMed 文献 · Ann Vasc Surg · 2025-11-13

该研究回顾性分析了2017年9月至2025年5月单中心连续1000例经颈动脉血运重建(TCAR)手术的围手术期及远期结局。技术成功率达98%,30天卒中、死亡和心肌梗死分别為1.9%、1.0%和0.2%,复合终点2.9%;平均随访18个月时同侧卒中3.4%、再狭窄/再干预1.7%、全因死亡6.6%。多变量分析显示既往卒中史和慢性阻塞性肺疾病是围手术期卒中/死亡的独立预测因素,而氯吡格雷使用和术中鱼精蛋白给药为保护因素。

要点

  • TCAR技术成功率高(98%),30天卒中/死亡/心梗复合终点低(2.9%)。
  • 既往卒中史(OR 2.4)和COPD(OR 1.7)增加围手术期卒中/死亡风险。
  • 氯吡格雷使用(OR 0.45)和术中鱼精蛋白(OR 0.47)与较低风险相关。

核心结论

  • TCAR在高危和标准风险患者中均表现出高技术成功率、低围手术期并发症和良好的远期结局。
  • 优化内科管理并根据合并症和既往神经系统事件进行风险分层可改善结局。
  • 需要随机试验来更好地定义TCAR与颈动脉内膜切除术的角色。

研究设计与样本

  • 回顾性分析前瞻性维护数据库,纳入2017年9月至2025年5月大型医疗系统内所有连续TCAR手术。
  • 共1000例TCAR手术,由23名外科医生完成,平均年龄74岁,31%为症状性狭窄。
  • 使用多变量逻辑回归识别30天内围手术期卒中或死亡的预测因素。

主要发现

  • 技术成功率为98%。
  • 30天卒中、死亡和心肌梗死发生率分别为1.9%、1.0%和0.2%,复合率为2.9%。
  • 中位住院时间为1天。
  • 平均随访18个月时,同侧卒中发生率为3.4%,再狭窄/再干预为1.7%,全因死亡率为6.6%。

关键数值与推荐

  • 既往卒中史:OR 2.4,P < 0.001,为围手术期卒中/死亡的独立预测因素。
  • 慢性阻塞性肺疾病:OR 1.7,P = 0.011,为独立预测因素。
  • 氯吡格雷使用:OR 0.45,P = 0.014,为保护因素。
  • 术中鱼精蛋白给药:OR 0.47,P = 0.011,为保护因素。

临床怎么用

  • TCAR可用于高危和标准风险患者,围手术期并发症低。
  • 对既往卒中史或COPD患者应加强风险分层和围手术期管理。
  • 氯吡格雷使用和术中鱼精蛋白给药可能与改善围手术期结局相关。

局限性

  • 回顾性设计。
  • 单机构/单医疗系统经验,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcarotid artery revascularization (TCAR) was developed to mitigate risks associated with both carotid endarterectomy and transfemoral carotid artery stenting. It is being performed in both high- and standard-risk patients. We report outcomes from the largest single-institution consecutive TCAR cohort to date. METHODS: A retrospective review was performed from a prospectively maintained database capturing all consecutive TCAR procedures performed across a large health system between September 2017 and May 2025. Demographics, perioperative variables, and short- and long-term outcomes were analyzed. A multivariable logistic regression was used to identify predictors of perioperative stroke or death within 30 days. RESULTS: A total of 1,000 TCAR procedures were performed by 23 surgeons. The mean age was 74 years. In all, 31% of patients presented with symptomatic stenosis. Technical success was achieved in 98%. Thirty-day stroke, death, and myocardial infarction occurred at 1.9%, 1.0%, and 0.2%, respectively, for a composite rate of 2.9%. The median length of stay was 1 day. At a mean follow-up of 18 months, ipsilateral stroke occurred in 3.4%, restenosis/reintervention in 1.7%, and all-cause mortality in 6.6%. Multivariable analysis identified prior stroke (odds ratio [OR] 2.4, P < 0.001) and chronic obstructive pulmonary disease (OR 1.7, P = 0.011) as independent predictors of perioperative stroke/death. Protective factors included clopidogrel use (OR 0.45, P = 0.014) and intraoperative administration of protamine (OR 0.47, P = 0.011). CONCLUSION: TCAR demonstrated high technical success, low perioperative morbidity, and favorable long-term outcomes in both high- and standard-risk patients. Optimal medical management and risk stratification by comorbidity and prior neurologic events improve outcomes. Randomized trials are needed to better define the roles of TCAR and carotid endarterectomy.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Dodwad SM, Dakour-Aridi H, Martin GH, et al. Perioperative and Follow-Up TCAR Outcomes of a Single Institution. Ann Vasc Surg. 2025. PMID: 41237976. doi:10.1016/j.avsg.2025.10.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。